Hemcon Medical Technologies Introduces Guardiva™ Advanced IV Dressing

Comments
Posted in News, Cardinal Health
Print
Continued from page 1

Central Venous Catheters (CVCs) and Peripherally Inserted Central Catheters (PICCs) are among the ideal applications for GuardIVa.  

 “We know there is a heightened focus on infection prevention, especially as it relates to catheter-related bloodstream infections,” said Debra Schotz, senior vice president of Patient Care at Cardinal Health. “By including GuardIVa in our portfolio in addition to our full line of Presource standard and custom kits, we’re helping our customers comply with recommendations from the Institute for Healthcare Improvement calling for maximal barrier protection and a kit or central line bundle to improve compliance for catheter insertion and maintenance procedures.” 2  

For product information, Cardinal Health customers should contact their nursing products or Presource sales representative. Information is also available through Cardinal Health by calling Jaime Simon at (614) 553-4663 for single sterile use or Crystal Humphreys at (614) 553-5263 for in-kit use.  

About HemCon Medical Technologies, Inc.
HemCon Medical Technologies Inc. is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including lyophilized human plasma and nanofiber technologies for wound care. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.

1 Bhende, Shubhangi, et. al.. “In vitro Antimicrobial Effectiveness of 5 Catheter Insertion-Site Dressings” The Journal of the Association for Vascular Access. Winter 2007. Vol 12 #4. GuardIVa & BioPatch: HemCon independent testing. Data on file at HemCon Medical Technologies Europe Ltd.
 
Online: ²http://www.ihi.org/IHI/Topics/CriticalCare/IntensiveCare/Changes/ImplementtheCentralLineBundle.htm
 

« Previous12Next »
Comments

Similar Articles

comments powered by Disqus